 |
|
 |
 |
|
Since the TEG® analyzer monitors the interaction of the plasma and cellular components of whole blood in the process of clotting and lysis, it lends itself to in vitro testing. For differential diagnosis, a TEG® sample of untreated blood is superimposed or analytically compared to a blood sample treated in vitro with blood components, e.g., fresh frozen plasma, cryoprecipitate, platelets, or pharmacological agents, e.g., amicar or protamine sulfate.[Kang] These tracings can easily differentiate in vitro which treated sample produces a normal tracing, and, therefore, normal coagulation. This provides a reduced-risk, low-cost, rapid way to determine treatment.
|
|
|
|
